Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives “Hold” Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research report report published on Tuesday morning, Benzinga reports.

Separately, StockNews.com upgraded shares of Lexicon Pharmaceuticals to a sell rating in a report on Monday, April 15th.

Lexicon Pharmaceuticals Stock Down 5.8 %

NASDAQ LXRX opened at $1.61 on Tuesday. Lexicon Pharmaceuticals has a 12 month low of $0.92 and a 12 month high of $3.79. The company’s 50 day simple moving average is $2.31 and its 200 day simple moving average is $1.72. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.60 and a quick ratio of 5.58. The company has a market capitalization of $396.44 million, a P/E ratio of -2.01 and a beta of 1.27.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.68 million. Equities research analysts expect that Lexicon Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Cantor Fitzgerald L. P. acquired a new position in Lexicon Pharmaceuticals in the 4th quarter valued at approximately $25,000. Principal Securities Inc. bought a new stake in Lexicon Pharmaceuticals in the fourth quarter worth approximately $33,000. TIAA Trust National Association bought a new stake in Lexicon Pharmaceuticals in the third quarter worth approximately $29,000. China Universal Asset Management Co. Ltd. grew its position in Lexicon Pharmaceuticals by 350.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 22,043 shares in the last quarter. Finally, RPO LLC bought a new stake in Lexicon Pharmaceuticals in the fourth quarter worth approximately $49,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.